ArticleBreast cancer (Dove Medical Press)2025
Prognostic and Immunological Implications of Telomere Maintenance-Related Genes in Breast Cancer: A Mechanistic Exploration.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PIMO: pathway-based interpretable multiomics interactions for multiomics integration.Bioinformatics (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The elongation of telomeres endows cancer cells with the ability of replicative immortality. Nevertheless, the connection between it and breast cancer (BC) has not been clearly defined yet. Methods: In this study, expression data from multiple BC datasets were analyzed to discover differentially expressed telomere maintenance-related genes (DE-TMRGs). Cox regression analyses were executed to determine prognostic genes, and a risk model was constructed using these genes to predict survival outcomes. Independent prognostic analysis was executed to assess independent prognostic factors. Enrichment analyses were conducted to determine pathways linked to the different risk groups. Immune infiltration levels and immune checkpoint expression were analyzed across risk categories using various algorithms. A regulatory network involving miRNAs and lncRNAs was constructed, and drug sensitivity was assessed. Mendelian randomization (MR) analysis was executed to investigate causal relationships between prognostic genes and BC. Finally, the expression of prognostic genes was further analysed at the single-cell level. Results: A sum of 81 DE-TMRGs. Through univariate and LASSO regression analyses, five prognostic genes (WT1, TPRXL, RAD54B, JUN, and SEPHS2) were identified to construct a risk model. This model successfully distinguished between high- and low-risk categories with significant differences in survival rates. Immune profiling revealed the high-risk category had increased levels of activated T cells. Eosinophil demonstrated a high correlation with prognostic genes. Furthermore, JUN (OR = 1.1333, P = 0.0085) and RAD54B (OR = 1.0790, P = 0.0015) were identified as causal risk factors for BC. Single-cell RNA sequencing highlighted JUN's widespread distribution across multiple cell types, suggesting its crucial role in tumor progression. Conclusion: TM-associated risk model based on WT1, TPRXL, RAD54B, JUN, and SEPHS2 could be used to predict prognosis and treatment of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.